

Approved by:



CERTIFICATE

2025

Teilgemeinschaftspraxis Molekularpathologie Südbayern
Giesinger Bahnhofplatz 2
81539 München
Deutschland

has successfully completed the proficiency test

HPV Cervical Cancer (MolPath)

(Trial Period 01.12.2025 - 19.12.2025)

Berlin, 9. März 2026

Prof. Dr. med. Claudia Wickenhauser
Quality in Pathology - QuIP GmbH

Thomas Pilz, Managing Director
Quality in Pathology - QuIP GmbH

Lead panel institute of the proficiency test:
Prof. Dr. med. G. Sauter, University Medical Center Hamburg-Eppendorf

This certificate includes the separate individual evaluation of the test and the corresponding proficiency test report, the evaluation criteria can be found in the proficiency test report under point 3.2.

This proficiency test was organized by:
Qualitätssicherungs-Initiative Pathologie QuIP GmbH /
Reinhardtstr. 1 / 10117 Berlin / office@quip.eu / www.qualityinpathology.com

